Professor Wu Lin: From 5 real cases, the efficacy and safety of sivotinib in clinical practice are seen

*For medical professionals only

In August, the essence of the met excellent case ~

Case 1: A 69-year-old female patient with invasive low-differentiated adenocarcinoma of the upper left lung with multiple lymph node metastases and multiple bone metastases (cT2aN2M1c, stage IVB) was diagnosed with an ECOG physical fitness status (PS) score of 3 points, genetic test results showed MET 14 exon jump mutation and MET amplification, and immunohistochemistry results were PD-L1 negative

With the development of molecular detection technology, more and more lung cancer driver genes have been discovered, and rare targets such as MET, RET, and HER2 have gradually become known

The main types of MET abnormalities in patients with NSCLC include MET14 exon-skipping mutations, MET amplification, MET overexpression, and MET fusion

The advent of highly selective MET-TKI has prolonged the survival time of MET anomalous NSCLC, which is undoubtedly a breakthrough in the treatment of MET anomalies

Judging from the treatment process of case 2, after the detection of MET amplification resistance, the case first chose osimertinib + zotinib for treatment, but 2 months later, the re-examination found that the lung lesion progressed, that is, PFS was only 2 months

Vice Chairman and Secretary General of CSWOG Lung Cancer Professional Committee of The Southern China Cancer Clinical Research Association (CSWOG).

Member of the Expert Committee of the Department of Oncology of the Oncology Branch of the Chinese Medical Association

Director of the Chinese Society of Clinical Oncology (CSCO).

Member of the Standing Committee of the Clinical Chemotherapy Professional Committee of the Chinese Anti-Cancer Association

Member of the Standing Committee of cmup committee of Chinese Anti-Cancer Association

Chairman of the Tumor Chemotherapy Professional Committee of Hunan Anti-Cancer Association

Chairman of tumor prevention and control branch of Hunan Health Service Industry Association

Vice President of oncologist Branch of Hunan Medical Doctor Association

Vice Chairman of the Targeted Therapy Professional Committee of Hunan Anti-Cancer Association

Vice Chairman of the Lung Cancer Professional Committee of Hunan Anti-Cancer Association

Vice Chairman of the Tumor Precision Medicine Professional Committee of Hunan Anti-Cancer Association

*This article is only used to provide scientific information to medical personnel and does not represent the views of this platform